Category Research

Encoded Therapeutics to Unveil ETX101 Clinical Data in Dravet Syndrome at ASGCT 2026 Presidential Symposium

Encoded Therapeutics to Present ETX101 Clinical Data in Dravet Syndrome at the 2026 ASGCT Presidential Symposium Encoded Therapeutics Inc. has announced its participation in the American Society of Gene & Cell Therapy 2026 Annual Meeting, where it will present new…

Read MoreEncoded Therapeutics to Unveil ETX101 Clinical Data in Dravet Syndrome at ASGCT 2026 Presidential Symposium

Mundipharma Reports Positive Phase III ReSPECT Results for REZZAYO in Preventing Invasive Fungal Infections

Mundipharma Reports Positive Phase III ReSPECT Topline Results for ▼REZZAYO (rezafungin) in Preventing Invasive Fungal Diseases in Allogeneic Stem Cell Transplant Patients Mundipharma has announced encouraging topline results from its pivotal Phase III ReSPECT clinical trial, highlighting the potential of…

Read MoreMundipharma Reports Positive Phase III ReSPECT Results for REZZAYO in Preventing Invasive Fungal Infections

Taiho Oncology, Taiho Pharmaceutical, and Araris Biotech Advance ADC Candidate ARC-02 into Phase 1 Clinical Trials

Taiho Oncology, Taiho Pharmaceutical, and Araris Biotech Advance ADC Candidate ARC-02 into Phase 1 Clinical Trials Taiho Oncology, Inc., together with Taiho Pharmaceutical Co., Ltd. and Araris Biotech AG, has announced a key regulatory milestone in the development of its…

Read MoreTaiho Oncology, Taiho Pharmaceutical, and Araris Biotech Advance ADC Candidate ARC-02 into Phase 1 Clinical Trials

Johnson & Johnson Initiates Landmark Head-to-Head Trial of Pulsed Field Ablation in Persistent Atrial Fibrillation

Johnson & Johnson Initiates Pivotal Head-to-Head Trial of Pulsed Field Ablation in Persistent Atrial Fibrillation Johnson & Johnson has announced the initiation of a landmark clinical study aimed at advancing the scientific understanding of pulsed field ablation (PFA), a rapidly…

Read MoreJohnson & Johnson Initiates Landmark Head-to-Head Trial of Pulsed Field Ablation in Persistent Atrial Fibrillation
Genentech

Genentech Teams Up with Damon Wayans and diaTribe to Launch ‘All Eyes on DME’ Campaign Targeting Diabetes-Related Vision Loss

Genentech Collaborates with Damon Wayans and diaTribe to Raise Awareness of Diabetes-Related Vision Loss Through ‘All Eyes on DME’ Campaign Genentech, a member of the Roche Group, has introduced a new awareness initiative aimed at addressing one of the most…

Read MoreGenentech Teams Up with Damon Wayans and diaTribe to Launch ‘All Eyes on DME’ Campaign Targeting Diabetes-Related Vision Loss

Reflow Medical Launches Next-Generation Cora Flex® and Cora Force® Torqueable Microcatheters in the U.S.

Reflow Medical Unveils U.S. Launch of Next-Generation Cora Flex® and Cora Force® Torqueable Microcatheters Reflow Medical, Inc. has announced the U.S. commercial launch of its next-generation Cora Flex® and Cora Force® Torqueable Microcatheters, marking a significant expansion of its coronary…

Read MoreReflow Medical Launches Next-Generation Cora Flex® and Cora Force® Torqueable Microcatheters in the U.S.

Study Links Muscle Composition to Elevated Chronic Kidney Disease Risk and Higher Mortality

New AMRA Study Links Muscle Composition to Elevated Risk of Chronic Kidney Disease and Increased Mortality AMRA Medical has released new research shedding light on an important and previously underappreciated factor influencing outcomes in patients with Chronic Kidney Disease. The…

Read MoreStudy Links Muscle Composition to Elevated Chronic Kidney Disease Risk and Higher Mortality

Kallyope Presents Phase 2b Data on Elismetrep, a Novel Migraine Therapy, at the American Academy of Neurology Annual Meeting

Kallyope Presents Phase 2b Data on Elismetrep, a Novel Migraine Therapy, at the American Academy of Neurology Annual Meeting Kallyope, a late-stage biopharmaceutical company focused on developing innovative treatments for neurological and metabolic disorders, has announced promising results from a…

Read MoreKallyope Presents Phase 2b Data on Elismetrep, a Novel Migraine Therapy, at the American Academy of Neurology Annual Meeting

Segal Trials Positioned to Support Next Wave of Clinical Development as Federal Fast-Tracking Boosts Psychedelic Therapies

As Federal Fast-Tracking of Psychedelic Treatments Gains Momentum, Segal Trials Is Poised to Advance the Next Stage of Clinical Development The recent federal directive encouraging the U.S. Food and Drug Administration to accelerate the review of psychedelic-based therapies signals a…

Read MoreSegal Trials Positioned to Support Next Wave of Clinical Development as Federal Fast-Tracking Boosts Psychedelic Therapies

From IVF Innovation to Skin Longevity: AV Laboratories Turns Biotechnology into Breakthrough Skincare

AV Laboratories Transforms IVF Science into Breakthrough Skin Longevity Innovations AV Laboratories is positioning itself at the forefront of a new era in skincare by bringing together decades of advanced biotechnology research and translating it into clinically inspired formulations designed…

Read MoreFrom IVF Innovation to Skin Longevity: AV Laboratories Turns Biotechnology into Breakthrough Skincare